CLEVELAND, OHIO — Convelo Therapeutics, Inc., a biotechnology company with a mission to discover a new class of medicines that regenerate the protective myelin coating around nerve cells, has entered into an exclusive worldwide collaboration with Genentech, a member of the Roche Group, to accelerate discovery and development of novel remyelinating medicines for patients with neurological disorders such as multiple sclerosis (MS).
Read MoreEnzymes downstream in cholesterol biosynthesis could provide new ways to stimulate remyelination that avoid the baggage of previously identified multiple sclerosis targets, according to a group at Case Western. The university is spinning out Convelo Therapeutics Inc. to translate the idea.
Read MoreWith research from Case Western Reserve University, a Cleveland-based startup aims to develop a new class of medicines that help regenerate the insulating myelin sheath around nerve cells, which is degraded in neurological disorders such as multiple sclerosis.
Read MoreConvelo Therapeutics launched publicly on Wednesday, July 25, after working in stealth mode with a mission to discover and develop a new class of medicines for neurological disease characterized by the loss of the protective Myelin coating around nerve cells, according to a news release.
Read MoreCLEVELAND, OHIO — Convelo Therapeutics, Inc. announced today that it has launched from stealth mode with a mission to discover and develop a new class of medicines that regenerate the protective myelin coating around nerve cells that is lost in a wide array of neurological diseases, including multiple sclerosis (MS). Seminal scientific discoveries made in the laboratories of Drs. Paul Tesar and Drew Adams at Case Western Reserve University School of Medicine provide the foundation of Convelo’s discovery platform. Their most recent work, published online today in the journals Nature and Nature Methods, identified a central molecular pathway for stimulating the regeneration of new myelinating cells in the central nervous system.
Read More